

# Simona Piemontese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5223547/publications.pdf>

Version: 2024-02-01

48  
papers

1,201  
citations

567281

15  
h-index

414414

32  
g-index

49  
all docs

49  
docs citations

49  
times ranked

2410  
citing authors

#	ARTICLE	IF	CITATIONS
1	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. <i>Clinical Immunology</i> , 2020, 215, 108450.	3.2	252
2	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	7.2	199
3	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	1.4	164
4	A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 24.	17.0	70
5	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1069-1075.	7.2	57
6	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 25.	17.0	57
7	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. <i>Haematologica</i> , 2016, 101, e352-e354.	3.5	49
8	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. <i>Blood</i> , 2016, 128, 1528-1531.	1.4	46
9	Two months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 912-920.	1.6	39
10	High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 629-636.	2.2	35
11	Control of infectious mortality due to carbapenemase-producing <i>Klebsiella pneumoniae</i> in hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 114-119.	2.4	33
12	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015, 100, 558-564.	3.5	29
13	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	1.2	26
14	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. <i>Frontiers in Immunology</i> , 2019, 10, 2319.	4.8	25
15	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	17.0	22
16	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). <i>Bone Marrow Transplantation</i> , 2021, 56, 2272-2275.	2.4	12
17	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 3359-3359.	1.4	11
18	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1389-1398.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency. <i>European Journal of Immunology</i> , 2022, 52, 1171-1189.	2.9	9
20	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 731478.	2.8	8
21	Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1106.	2.4	8
22	COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2312-2315.	2.4	7
23	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1022-1024.	2.4	6
24	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. <i>Hematological Oncology</i> , 2016, 34, 154-160.	1.7	6
25	Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 672-672.	1.4	6
26	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. <i>Frontiers in Oncology</i> , 2021, 11, 705568.	2.8	4
27	Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 678-680.	2.4	4
28	Acute respiratory distress in a neutropenic febrile patient after hematopoietic cell transplantation. <i>Journal of Clinical Virology</i> , 2013, 57, 1-4.	3.1	2
29	Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients. <i>Blood</i> , 2015, 126, 4400-4400.	1.4	1
30	Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients. <i>Blood</i> , 2016, 128, 3442-3442.	1.4	1
31	Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia. <i>Blood</i> , 2016, 128, 5810-5810.	1.4	1
32	Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients. <i>Blood</i> , 2018, 132, 4600-4600.	1.4	1
33	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	2.4	1
34	Secondary SOLID Tumors after Allogeneic STEM CELL Transplantation: A CROSS-Sectional Evaluation in 260 Adults at 1-Year Follow-up. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S189-S190.	2.0	0
35	Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type. <i>Current Research in Translational Medicine</i> , 2021, 69, 103313.	1.8	0
36	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA mismatching barrier. <i>Transplant Infectious Disease</i> , 2021, 23, e13551.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Intensification Of Treosulfan and Fludarabine-Based Conditioning With 4 Gy TBI For Allogeneic Stem Cell Transplantation In Patients With Hematological Malignancies. <i>Blood</i> , 2013, 122, 2149-2149.	1.4	0
38	Unmanipulated Graft Haploidentical Allogeneic Stem Cell Transplantation (Haplo-SCT) In Acute Leukemia: A Long-Term Follow-Up Survey On Behalf Of The Acute Leukemia Working Party (ALWP) Of The European Group For Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2013, 122, 2105-2105.	1.4	0
39	Matched and Mismatched Unrelated Donor Versus Unmanipulated Haploidentical Donors for Hematopoietic Cell Transplantation in Acute Leukemia in Remission: A Pair Matched Analysis on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2014, 124, 1219-1219.	1.4	0
40	Haploidentical Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: A Matched Pair Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2014, 124, 2508-2508.	1.4	0
41	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014, 124, 1227-1227.	1.4	0
42	Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 4335-4335.	1.4	0
43	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. <i>Blood</i> , 2015, 126, 4362-4362.	1.4	0
44	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. <i>Blood</i> , 2015, 126, 5465-5465.	1.4	0
45	Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3492-3492.	1.4	0
46	Biomarkers Predicting Acute GvHD and Transplant Outcomes in 120 Consecutive Allogeneic HSCT Recipients. <i>Blood</i> , 2016, 128, 2240-2240.	1.4	0
47	Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy. <i>Blood</i> , 2016, 128, 4567-4567.	1.4	0
48	Post-Transplant Cyclophosphamide and Sirolimus in Matched Related and Unrelated Allogeneic Transplant with a Treosulfan-Based Conditioning. <i>Blood</i> , 2018, 132, 4662-4662.	1.4	0